KR20210125532A - 진단 및 치료 목적을 위한 엑소좀 관련 마이크로바이옴의 단리 및 검출 - Google Patents

진단 및 치료 목적을 위한 엑소좀 관련 마이크로바이옴의 단리 및 검출 Download PDF

Info

Publication number
KR20210125532A
KR20210125532A KR1020217028785A KR20217028785A KR20210125532A KR 20210125532 A KR20210125532 A KR 20210125532A KR 1020217028785 A KR1020217028785 A KR 1020217028785A KR 20217028785 A KR20217028785 A KR 20217028785A KR 20210125532 A KR20210125532 A KR 20210125532A
Authority
KR
South Korea
Prior art keywords
cancer
microbial
patient
exosomes
microbiome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217028785A
Other languages
English (en)
Korean (ko)
Inventor
라구 칼루리
Original Assignee
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 filed Critical 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템
Publication of KR20210125532A publication Critical patent/KR20210125532A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/6893—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for protozoa
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/574—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020217028785A 2019-02-08 2020-02-07 진단 및 치료 목적을 위한 엑소좀 관련 마이크로바이옴의 단리 및 검출 Ceased KR20210125532A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962802994P 2019-02-08 2019-02-08
US62/802,994 2019-02-08
PCT/US2020/017224 WO2020163724A1 (en) 2019-02-08 2020-02-07 Isolation and detection of exosome-associated microbiome for diagnostic and therapeutic purposes

Publications (1)

Publication Number Publication Date
KR20210125532A true KR20210125532A (ko) 2021-10-18

Family

ID=71947984

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217028785A Ceased KR20210125532A (ko) 2019-02-08 2020-02-07 진단 및 치료 목적을 위한 엑소좀 관련 마이크로바이옴의 단리 및 검출

Country Status (8)

Country Link
US (1) US20220137056A1 (https=)
EP (1) EP3921325A4 (https=)
JP (1) JP2022519326A (https=)
KR (1) KR20210125532A (https=)
CN (1) CN113631725A (https=)
AU (1) AU2020218358A1 (https=)
CA (1) CA3129250A1 (https=)
WO (1) WO2020163724A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3775258A4 (en) 2018-03-28 2022-01-26 Board of Regents, The University of Texas System IDENTIFICATION OF EPIGENETIC ALTERATIONS IN DNA ISOLATED FROM EXOSOMES
WO2021158966A1 (en) 2020-02-05 2021-08-12 Board Of Regents, The University Of Texas System Diagnostic and prognostic utility of exosomes in immunotherapy
EP4373976A4 (en) * 2021-07-20 2025-06-18 Liquid Biopsy Holdco, LLC METHODS FOR DIAGNOSIS OF DISEASE USING MICROBIAL EXTRACELLULAR VESICLE (MEV) ANALYTES
CN114486829B (zh) * 2022-01-24 2023-06-27 复旦大学 一种微量外泌体捕集并计数的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9807045D0 (en) * 1998-04-01 1998-06-03 Rudi Knut Nucleic acid detection method
KR101810799B1 (ko) * 2008-02-01 2017-12-19 더 제너럴 하스피탈 코포레이션 의학적 질환 및 병태의 진단, 예후, 및 치료에 있어서 미세소포체의 용도
WO2010056337A2 (en) * 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
WO2011027956A2 (ko) * 2009-09-04 2011-03-10 주식회사이언메딕스 그람 양성 박테리아에서 유래한 세포밖 소포체 및 이를 이용한 질병 모델
US20130029339A1 (en) * 2009-09-09 2013-01-31 The General Hospital Corporation Use of microvesicles in analyzing kras mutations
CA2846804A1 (en) * 2011-08-26 2013-03-07 Microbiota Diagnostics, Llc Methods for diagnosing and treating cardiac defects
US20150176073A1 (en) * 2012-07-18 2015-06-25 Exosome Diagnostics, Inc. Use of microvesicles in diagnosis, prognosis, and treatment of medical diseases and conditions
US9921223B2 (en) * 2013-12-04 2018-03-20 Board Of Regents, The University Of Texas System Analysis of genomic DNA, RNA, and proteins in exosomes for diagnosis and theranosis
KR101798176B1 (ko) * 2014-12-16 2017-11-15 주식회사 엠디헬스케어 세균 유래의 나노소포체를 이용한 세균성 감염질환 원인균 동정방법
KR101726488B1 (ko) * 2015-02-23 2017-04-13 이화여자대학교 산학협력단 바실러스 속 세균 유래 세포밖 소포체를 포함하는 임신관련 질환 치료용 조성물
US10526665B2 (en) * 2016-03-04 2020-01-07 University Of Notre Dame Du Lac Exosomal biomarkers diagnostic of tuberculosis
JP2018063182A (ja) * 2016-10-13 2018-04-19 国立大学法人 新潟大学 腸内細菌の菌叢分析方法及び被検体におけるヘリコバクター・ピロリに対するアレルギーの検出方法
KR20180076308A (ko) * 2016-12-26 2018-07-05 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 췌장암 진단방법
WO2018124618A1 (ko) * 2016-12-26 2018-07-05 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 췌장암 진단방법
KR101940426B1 (ko) * 2016-12-28 2019-01-18 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 대장종양 진단 방법
WO2018124735A1 (ko) * 2016-12-28 2018-07-05 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 대장종양 진단 방법
AU2018239339A1 (en) * 2017-03-23 2019-10-03 Penn State Research Foundation Method for diagnosing or monitoring conditions characterized by abnormal temporal variations method of normalizing epigenetic data to compensate for temporal variations

Also Published As

Publication number Publication date
EP3921325A4 (en) 2022-11-23
CN113631725A (zh) 2021-11-09
JP2022519326A (ja) 2022-03-22
EP3921325A1 (en) 2021-12-15
AU2020218358A1 (en) 2021-08-26
US20220137056A1 (en) 2022-05-05
WO2020163724A1 (en) 2020-08-13
CA3129250A1 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
Cai et al. Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer
JP5416110B2 (ja) ｉｎｖｉｖｏ細胞死を検出するためにｍｉＲＮＡを使用する方法
US10472599B2 (en) Microfluidic cell culture of patient-derived tumor cell spheroids
KR20210125532A (ko) 진단 및 치료 목적을 위한 엑소좀 관련 마이크로바이옴의 단리 및 검출
Ye et al. CircRNA_103765 acts as a proinflammatory factor via sponging miR-30 family in Crohn’s disease
JP2010536372A5 (https=)
US9857375B2 (en) Cancer marker and utilization thereof
Huang et al. CircKIAA0182-YBX1 axis: A key driver of lung Cancer progression and chemoresistance
CN107557472B (zh) 胶质瘤诊断标志物circ9:135881633|135883078及应用
Özkan et al. Human Organ Chips Reveal New Inflammatory Bowel Disease Drivers
CN110295172B (zh) 一种快速筛选的肾癌核酸适体及其制剂在制备检测中的应用
CN107937532B (zh) 胶质瘤诊断标志物hsa_circ_0021827及应用
Zhao et al. HMGA1 influence on iron-induced cell death in Tfh cells of SLE patients
CN106148337B (zh) 长非编码rna ay927503及其用途
Zhang et al. Longitudinal Monitoring of Glioblastoma Small Extracellular Vesicle Evolution Using a Nanodiagnostic to Detect Emergence of Glioma Stem Cells Driving Recurrent Disease
CN107557441B (zh) 胶质瘤诊断标志物Circ2:23823258|23823569及应用
CN107557471B (zh) 胶质瘤诊断标志物Circ6:22020339|22020542及应用
CN116622835B (zh) lncRNA CASC15作为肝纤维化生物标志物的应用
CN105950705A (zh) 一组microRNAs在制备阿尔兹海默氏症诊断试剂或诊断试剂盒中的应用
JP6041297B2 (ja) 犬リンパ腫の診断方法及び診断キット
Dieckman et al. BASIC
CN107604076A (zh) 胶质瘤诊断标志物Circ6:4891713|4892379及应用
CN107586843A (zh) 胶质瘤诊断标志物circ7:100812747|100813208及应用
CN107586846A (zh) 胶质瘤诊断标志物Circ3:129880309|129880559及应用
Dieckman et al. Mahfouz

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601